Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of upadacitinib in Crohn's disease
NL-OMON59237Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of upadacitinib in Crohn's disease, sponsored by AbbVie Inc. Primary endpoints: Proportion of subjects achieving remission, Maintenance of remission and 17 more. Started Feb 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59237.